Clicky

Ligand Pharmaceuticals Incorporated(LGDN)

Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.


Keywords: Biopharmaceutical Diabetes Autoimmune Disease Breast Cancer Multiple Myeloma Orphan Drug Osteoporosis Acute Lymphoblastic Leukemia Pneumonia Type 1 Diabetes Asparaginase Immunoglobulin A Nephropathy Postpartum Depression Kyprolis Teplizumab Pneumococcal Conjugate Vaccine Injection Product Ligand Pharmaceuticals Lymphoblastic Lymphoma Streptococcus Pneumoniae Teriparatide Treatment Of Acute Lymphoblastic Leukemia

Home Page: www.ligand.com

555 Heritage Drive
Jupiter, FL 33458
United States
Phone: 858 550 7500


Officers

Name Title
Mr. Todd C. Davis Ph.D. CEO & Director
Mr. Octavio Espinoza Chief Financial Officer
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development
Michael Jeong Head of Investor Relations
Mr. Todd Pettingill C.F.A. Director of Corporate Development
Dr. Keith Marschke Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol
Mr. Patrick Lucy Senior VP & CBO Protein Expression Business
Dr. Karen R. Reeves M.D. Senior VP of Investments & Head of Clinical Strategy

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 21.1416
Trailing PE: 49.3617
Price-to-Book MRQ: 2.7582
Price-to-Sales TTM: 14.5654
IPO Date:
Fiscal Year End: December
Full Time Employees: 58
Back to stocks